GAITHERSBURG, Md., June 22, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- MedImmune, Inc.
(Nasdaq: MEDI) today announced the pricing of $500 million principal amount of
Convertible Senior Notes due 2011 (the "2011 notes") and $500 million
principal amount of Convertible Senior Notes due 2013 (the "2013 notes" and,
collectively with the 2011 notes, the "notes"), through offerings to qualified
institutional buyers pursuant to Rule 144A under the Securities Act of 1933,
as amended (the "Securities Act"). MedImmune has granted the initial
purchasers an option to purchase up to an additional $75 million aggregate
principal amount of 2011 notes and up to an additional $75 million aggregate
principal amount of 2013 notes, in each case solely to cover over-allotments.
The 2011 notes will pay interest semiannually at a rate of 1.375% per
annum, and the 2013 notes will pay interest semiannually at a rate of 1.625%
per annum. The notes will be convertible, in certain circumstances, into a
combination of cash and MedImmune common stock. In general, upon conversion,
the holder of each note would receive the conversion value of the note payable
in cash up to the principal amount of the note and MedImmune common stock for
the note's conversion value in excess of such principal amount based on a
conversion rate of 29.9679 shares of common stock per $1000 principal amount
of the notes, which is equal to a conversion price of approximately $33.37 per
In connection with the offering of the notes, MedImmune is entering into
convertible note hedge and warrant transactions with two of the initial
purchasers or their affiliates. Taken together, the convertible note hedge and
warrant transactions are expected to reduce the potential dilution upon
conversion of the notes. These transactions will generally have the effect on
the company of increasing the conversion price of the notes to approximately
$47.67 per share, representing a 75 percent premium based on the closing price
of $27.24 per share on June 22, 2006.
Should the initial purchasers exercise their over-allotment options,
MedImmune intends to use a portion of the net proceeds from the sale of the
additional notes, together with the proceeds from additional warrant
transactions, to enter into additional convertible note hedge transactions.
MedImmune anticipates that holders of its currently outstanding 1%
convertible senior notes will exercise their right, as provided in the related
indenture, to require it to repurchase those notes as of July 17, 2006 at a
price equal to 100 percent of the principal amount plus any accrued and unpaid
interest. MedImmune expects to use approximately $500 million of the proceeds
to fund the repurchase of the 1% convertible senior notes. In addition,
MedImmune expects to use up to $150 million of the net proceeds to purchase
shares of its common stock in privately negotiated transactions concurrently
with the offering of the notes. Further, MedImmune estimates that the cost of
the convertible note hedge that is not covered by the proceeds from the sale
of the warrants will be approximately $121 million. Any remaining proceeds
will be added to MedImmune's working capital and will be used for general
corporate purposes, including potential acquisitions, in-licensing and
collaboration opportunities, and additional share repurchases, pursuant to the
company's recently announced $500 million share buyback program.
Following the pricing and in connection with the convertible note hedge
and warrant transactions, it is expected that the counterparties to such
transactions may continue to enter into, or to unwind, various derivatives
transactions with respect to MedImmune's common stock and/or to purchase or
sell shares of the company's common stock in secondary market transactions,
including during the cash settlement averaging period relating to any
conversion of the notes.
This notice does not constitute an offer to sell or a solicitation of an
offer to buy securities. Any offers of the securities will be made only by
means of a private offering memorandum. The securities offered have not been
registered under the Securities Act or the securities laws of any other
jurisdiction and may not be offered or sold in the United States absent
registration or an applicable exemption from registration requirements.
SOURCE MedImmune, Inc.
Investors: Peter Vozzo, +1-301-398-4358, or Media: Jamie Lacey, +1-301-398-4035, both
of MedImmune, Inc.